Quick Take
Oyster Point Pharma (OYST) has filed to raise gross proceeds of $85 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing treatments for ocular surface diseases.
OYST has produced very promising results in Phase 2b trials for its lead candidate for the treatment of dry eye disease.
Company & Technology
Princeton, New Jersey-based Oyster Point was founded in 2006 to develop new therapeutics for the treatment of eye diseases.
Management is headed by CEO and Director Jeffrey Nau, who has been with the firm since